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pathways such as farnesoid X receptor- and liver X recep-
tor-mediated responses, which are known to play a role in 
cholestasis, were significantly affected by all cholestatic 
compounds. Other significantly affected pathways include 
unfolded protein response and protein ubiquitination impli-
cating the role of endoplasmic reticulum stress. This study 
shows that human PCLS incubated in the presence of a 
physiological bile acid mixture correctly reflect the path-
ways affected in drug-induced cholestasis in the human 
liver. In the future, this human PCLS model can be used to 
identify cholestatic adverse drug reactions of new chemical 
entities.
Keywords Cholestasis · Hepatotoxicity · Precision-cut 
liver slices · Transcriptomics
Introduction
Drug-induced hepatotoxicity (DILI) is one of the major 
reasons for failure of drugs in the drug development or 
post-marketing phase, leading to withdrawal of drugs from 
development or from the market, respectively. It is of major 
concern for the consumers, regulatory authorities such as 
the FDA and the EMA and pharmaceutical companies. In 
the drug discovery process, valuable information about 
possible mechanisms of toxicity is gained by exposing a 
compound to suitable ex vivo, in vitro or in vivo models. 
The possibility to determine early in the drug development 
process whether a compound causes a particular pathol-
ogy results in valuable information about the mechanism of 
action of an as yet uncharacterized compound.
One of the major causes for DILI is cholestasis. Choles-
tasis is characterized as inhibition of bile flow caused by a 
variety of mechanisms that can involve not only elements 
Abstract Hepatotoxicity is one of the major reasons for 
withdrawal of drugs from the market. Therefore, there is 
a need to screen new drugs for hepatotoxicity in humans 
at an earlier stage. The aim of this study was to validate 
human precision-cut liver slices (PCLS) as an ex vivo 
model to predict drug-induced cholestasis and identify the 
possible mechanisms of cholestasis-induced toxicity using 
gene expression profiles. Five hepatotoxicants, which are 
known to induce cholestasis (alpha-naphthyl isothiocy-
anate, chlorpromazine, cyclosporine, ethinyl estradiol and 
methyl testosterone) were used at concentrations inducing 
low (<30 %) and medium (30–50 %) toxicity, based on 
ATP content. Human PCLS were incubated with the drugs 
in the presence of a non-toxic concentration (60 µM) of a 
bile acid mixture (portal vein concentration and composi-
tion) as model for bile acid-induced cholestasis. Regulated 
genes include bile acid transporters and cholesterol trans-
porters. Pathway analysis revealed that hepatic cholestasis 
was among the top ten regulated pathways, and signaling 
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of the biliary tree, including the bile ducts and ductules, 
but also the transporters in the basolateral or canalicular 
membrane, as well as disruption of the tight junctions of 
the hepatocytes. BSEP inhibition is a common cause of 
cholestasis, and the resulting accumulation of bile acids in 
the hepatocytes triggers a direct cellular response, which is 
associated with apoptosis, inflammation, oxidative stress 
and endoplasmic reticulum stress and cell death. It also 
causes adaptive cellular responses mediated via nuclear 
receptors (Vinken et al. 2013).
Most of the information has been obtained from in vivo 
models such as bile duct ligation in different animal spe-
cies, but mechanistic information on human liver in vivo is 
very scarce. In addition, in vitro models such as human and 
rat hepatocytes, HepG2 and HepaRG cells have been inves-
tigated as predictive model. Ansede et al. (2010) published 
an in vitro assay to assess the transporter-based inhibition 
of excretion of a tracer concentration of bile acid using 
sandwich-cultured rat hepatocytes. But as bile acids are 
only present at very low concentration, this model may not 
detect bile acid-dependent toxicity. In contrast, Ogimura 
et al. (2011) incubated sandwich-cultured rat hepatocytes 
with cholestatic compounds in the presence of bile acids 
to develop an experimental model reflecting bile acid-
dependent cholestatic injury. Both models were developed 
with rat hepatocytes, and extrapolation of the results to pre-
dict human cholestatic injury remains hazardous. Recently, 
Chatterjee et al. (2014) showed that indeed a model with 
sandwich-cultured human hepatocytes in the presence of 
bile acids predicts the cholestatic potential of drugs more 
accurately in human than rat hepatocytes. However, it is 
well known that the hepatocytes show dedifferentiation 
during culture, which is accompanied by a decrease in 
drug metabolism capacity and unphysiological expression 
of transporters (Fraczek et al. 2013). Therefore, predic-
tions based on sandwich cultures may not always be very 
precise.
In the present study, we aimed to investigate whether 
human precision-cut liver slices (PCLS) in the presence of 
a physiological concentration of bile acids could be used 
as a predictive model for drug-induced bile acid-dependent 
cholestatic injury. PCLS have been shown to be a viable 
ex vivo tool to study the metabolism and toxicity of xeno-
biotics for over a decade (de Graaf et al. 2010). Recently, 
mouse PCLS were used as a model to identify the mecha-
nisms of drug-induced cholestasis (Szalowska et al. 2013), 
but also, this mouse model is prone to problems of species 
extrapolation and no bile acids were present during the 
incubation. The possibility to use human tissue for toxic-
ity studies helps to reduce unnecessary animal studies and 
to identify human specific toxicity. Advantages of this 
PCLS model include the presence of all cells of the tissue 
in their natural environment with intact inter-cellular and 
cell–matrix interactions, stable expression of drug metab-
olizing and detoxification enzymes, the ability to produce 
bile acids and most importantly polarized physiological 
expression of transporters. This model is therefore highly 
appropriate for studying multicellular drug toxicity pro-
cesses (van de Bovenkamp et al. 2005; Elferink et al. 2008, 
2011; Hadi et al. 2013; Westra et al. 2014; Vatakuti et al. 
2015). Elferink et al. (2008) used transcriptomics analy-
sis to show that rat PCLS reflect the proper mechanisms 
of hepatotoxicity. Moreover, they showed that in human 
PCLS the gene expression profiles of genes related to drug 
metabolism, transport and toxicity remain fairly constant 
during 24 h of incubation but that these profiles are affected 
by paracetamol-induced toxicity. However, up to now, no 
transcriptomics data on human PCLS exposed to chole-
static compounds have been reported. Since the primary 
event involved in the majority of drug-induced cholestasis 
in vivo is accumulation of bile acids due to inhibition of 
export transporters such as BSEP, we hypothesized that to 
further optimize the PCLS to mimic cholestasis induced by 
accumulation of the bile acids in vivo, the PCLS should be 
incubated with a non-toxic concentration of a bile acid mix 
mimicking the portal vein bile acid concentration and com-
position. Therefore, in this study, we exposed human PCLS 
to drugs or chemicals known to induce cholestasis such 
as alpha-naphthyl isothiocyanate (ANIT), cyclosporine, 
chlorpromazine, ethinyl estradiol and methyl testosterone 
at different concentrations inducing low-to-moderate tox-
icity based on decrease in ATP content in the presence of 
a physiological bile acid mix. To detect cholestatic injury 
and the mechanisms involved, the profiles of differentially 
expressed genes were analyzed using IPA pathway analy-
sis. Moreover, they were compared to expression profiles of 
human in vivo late-stage cholestasis caused by biliary atre-
sia and intrahepatic cholestasis.
Materials and methods
Chemicals
Alpha-naphthylisothiocyanate (ANIT), chlorpromazine 
(CP), cyclosporine (CS), ethinyl estradiol (EE) and methyl 
testosterone (MT) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Stock solutions for all compounds were 
prepared in DMSO (VWR, Briare, France).
Human liver tissue
Human liver tissue was obtained from the remaining liver 
tissue after split liver transplantation (TX). The charac-
teristics of the human livers used in the experiments are 
described in Table 1. The experimental protocols were 
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approved by the Medical Ethical Committee of the Univer-
sity Medical Center, Groningen.
Preparation and incubation of human PCLS
Precision-cut liver slices of 5 mm diameter and 250 μm 
thickness were prepared (de Graaf et al. 2010). At this 
thickness, full penetration of substrates has been shown. 
PCLS were made using the Krumdieck tissue slicer (Ala-
bama R&D, Munford, AL, USA) in ice-cold Krebs buffer 
at pH 7.42, enriched with glucose to a final concentration 
of 25 mM, saturated with carbogen (95 % O2/5 % CO2). 
Immediately after the slices were made, they were placed 
in ice-cold University of Wisconsin organ preservation 
solution (UW, Dupont Critical Care, Waukegan, IL, USA) 
and stored on ice until the beginning of the experiment. 
Slices were pre-incubated individually in 12-well plates 
in 1.3 ml of Williams Medium E with glutamax-1 (Gibco, 
Invitrogen, Paisley, Scotland) supplemented with 25 mM 
d-glucose and 50 μg/ml gentamycin (Gibco, Invitrogen, 
Paisley, Scotland). In the incubator (Sanyo CO2/O2 Incu-
bator, PANASONIC, Secaucus, NJ, USA), the plates were 
gently shaken (90 times/min) for 1 h under 80 % O2 and 
5 % CO2 atmosphere at 37 °C. This pre-incubation allows 
the slices to restore their ATP levels. After pre-incubation, 
the slices were moved to different well plates filled with 
1.3 ml Williams Medium E with glutamax-1 supplemented 
with 25 mM d-glucose, 50 μg/ml gentamycin, 60 μM 
human bile acid mix (Table 2) and different concentra-
tions of the compounds such as ANIT (25, 50 and 75 μM), 
chlorpromazine (10, 20 and 30 μM), cyclosporine (9, 12 
and 15 μM), ethinyl estradiol (25, 50 μM and 75 μM) 
and methyl testosterone (50, 75 and 100 μM) or solvent 
(DMSO). These concentrations were selected from pilot 
experiments where a larger concentration range was used to 
detect concentrations that resulted in low-to-medium toxic-
ity. The plates were incubated under the same conditions 
for 24 h. All incubation conditions were carried out in trip-
licate. Each experiment was performed in slices of 6 differ-
ent human livers (Table 1). Slices were harvested for ATP 
assay in 100 mM Tris buffer with 2 mM EDTA and for 
RNA isolation in RNAlater. The bile acid mix was added to 
the medium in order to create an environment similar to the 
physiological concentration in the portal vein. The com-
position of the serum bile acids was according to Scherer 
et al. (2009). Pilot experiments were performed to find out 
the non-toxic concentration of the bile acid mix. A series of 
concentrations (10–200 μM) of the bile acid mix contain-
ing the 14 different bile acids (BA) shown in Table 2 were 
tested. Concentrations up to 60 μM were found to be non-
toxic, and hence, further experiments were performed using 
a concentration of 60 μM, which is close to the reported 
portal vein bile acid concentration (Scherer et al. 2009). 
The final concentrations of the bile acids in the incubation 
medium are presented in Table 2.
Viability assay: ATP and protein content of PCLS
The viability of PCLS was assessed by the content of ATP. 
The determination of ATP was performed using the ATP 
Bioluminescence Assay Kit CLS II (Roche, Mannheim, 
Germany). Three slices were harvested in a 2 mM EDTA 
solution containing 70 % ethanol, pH 10.9, and immedi-
ately frozen at −80 °C. Slices were homogenized using a 
mini beat beater, and the homogenate was centrifuged for 
5 min at 13,000g. The supernatant was used for the ATP 
assay and the pellet for the protein analysis. The ATP assay 
is performed in 96-well plate; 5 μL of sample was diluted 
10 times with 100 mM Tris–HCl, 2 mM EDTA buffer pH 
7.8; and 50 μL of luciferase was added to each sample, 
and the ATP was measured with the Lucy1 luminometer 
(Anthos, Durham, NC, USA). The protein content of each 
Table 1  Demographics of donors of human liver tissue used for the 
experiments







Table 2  Composition of human bile acids mix
Composition of bile acids Final concentration in the 
incubation medium (µM)
Cholic acid (CA) 2.65
Chenodeoxycholic acid (CDCA) 4.51




Glycocholic acid (GCA) 5.44




Hyodeoxycholic acid (HDCA) 2.79
Lithocholic acid (LCA) 0.40




Taurolithocholic acid (TLCA) 1.15
Taurodeoxycholic acid (TDCA) 0.58
Ursodeoxycholic acid (UDCA) 1.46
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slice was assessed using the Bio-Rad DC protein assay 
kit (Bio-Rad, Munich, Germany) as described before (de 
Graaf et al. 2010), and the ATP values are corrected with 
their corresponding protein content, which shows some 
variation, due to the presence of large blood vessels and 
small variations in the diameter between individual slices, 
but does not change during 24-h incubation (unpublished 
observations). As shown before (de Graaf et al. 2010), dif-
ferent human livers have different basal ATP levels. Data 
normalization was performed to account for the inter-indi-
vidual differences. The response (decrease in ATP) to each 
of the tested concentrations of the cholestatic compounds 
was expressed relative to the corresponding control ATP 
values of PCLS of the same donor incubated under identi-
cal conditions but without the drug.
RNA isolation
RNA was isolated from slices with <10, <30 and 30–50 % 
decreased viability. Maxwell® 16 LEV Total RNA purifi-
cation kit (Promega, The Netherlands) with Maxwell® 16 
LEV Instrument was used to isolate RNA from the sam-
ples. Immediately after isolation, the RNA quality was 
assessed by measuring the 260/280 and 260/230 ratios, and 
the concentration was measured with the ND-1000 spec-
trophotometer (Fisher Scientific, Landsmeer, The Nether-
lands). The quality (RIN value) and quantity of the RNA 
were determined by high-throughput Caliper GX LabChip 
RNA kit (Caliper).
Amplification, labeling and hybridization of RNA 
samples
Ambion Illumina Total Prep RNA kit was used to tran-
scribe 300 ng RNA to cRNA according to the manufactur-
er’s instructions. A total of 750 ng of cRNA was hybridized 
at 58 °C for 16 h to the Illumina HumanHT-12 v4 Expres-
sion BeadChips. BeadChips were scanned using Iscan soft-
ware, and IDAT files were generated (Illumina, San Diego, 
CA, USA).
Preprocessing of gene expression data
GenomeStudio software (Illumina) was used to read the 
IDAT files and generate raw expression values. The Array-
Analysis web service (www.arrayanalysis.org/) was used 
for further preprocessing the data, which uses lumi R pack-
age (Eijssen et al. 2013). Raw gene expression data were 
background-corrected (bgAdjust), variance-stabilized 
(VST) and normalized by quantile normalization. After 
normalization, the data were corrected for batch differ-
ences owing to RNA isolation and hybridization using the 
ComBat method implemented in the swamp package in R 
(Lauss et al. 2013). Differentially expressed genes in slices 
exposed to the cholestatic drugs in the presence of bile 
acids versus the slices exposed to vehicle (DMSO) in the 
presence of bile acids were identified using the unpaired 
moderated t test in the limma package (Ritchie et al. 2015). 
Genes that are regulated with a criterion of fold change of 
1.5 (≤ or ≥1.5), and FDR-corrected p value ≤0.05 (Ben-
jamini and Hochberg method) were chosen for pathway 
analysis. To compare our data with the scarcely available 
human in vivo data, human in vivo late-stage cholestasis 
data were downloaded from the Gene Expression Omni-
bus database (GSE46960). These gene expression data 
were generated in GeneChip Human Gene 1.0 ST array 
(Affymetrix, CA), hybridization experiments using human 
liver biopsies obtained from 64 infants with biliary atre-
sia, 14 age-matched infants with cholestasis of other origin 
than biliary atresia and from 7 deceased healthy children 
(Bessho et al. 2014). Affymetrix data normalization and 
statistical analysis were performed using the ArrayAnalysis 
Web site (Eijssen et al. 2013) using the same criteria as for 
the PCLS.
A gene is considered as regulated in association with 
cholestasis in human PCLS if its expression is differen-
tially regulated in the same direction by two or more of the 
five tested compounds. A gene is considered as regulated 
in vivo in human if its expression is differentially regulated 
in either biliary atresia or intrahepatic cholestasis.
Pathway analysis
Canonical metabolic and signaling pathway analysis was 
performed using QIAGEN’s Ingenuity® Pathway Analy-
sis (IPA®, QIAGEN Redwood City, California, USA). The 
compound exposures where no or very few genes were 
regulated (25 µM AN, 10 and 20 µM CP 25 and 50 µM EE 
and 25 µM MT) were excluded from the pathway analysis. 
Comparison pathway analysis feature in IPA was used to 
compare the canonical pathways affected by the different 
compounds in human PCLS.
Results
In this study, human PCLS were pre-incubated for 1 h to 
restore their ATP levels after storage and processing and 
subsequently incubated for 24 h in the presence of a physi-
ological concentration of bile acids and in the presence and 
absence of various concentrations of well-known choles-
tatic compounds. Transcriptomics analysis was performed 
on samples showing low (<30 %) or medium (30–50 %) 
decrease in viability, to understand the mechanistic events 
involved in drug-induced cholestasis. Differentially regu-
lated genes were identified, and pathway analysis was 
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performed to understand the mechanistic role of the regu-
lated genes as described below.
Concentration selection for transcriptomic studies
Concentration response studies were performed to identify 
toxic concentrations for the cholestatic compounds. Pilot 
studies were performed using a range of concentrations 
(data not shown), and the concentrations which showed a 
10–30 and 30–50 % decrease in ATP for each of the tested 
cholestatic compounds were chosen for the microarray 
gene expression studies. All five cholestatic compounds 
showed a concentration-dependent decrease in cell viability 
(supplementary data Figure 1). Despite some inter-individ-
ual differences in sensitivity for the drugs, for each human 
liver, the concentrations that caused low (<30 % decrease 
in ATP) and medium toxicity (30–50 % decrease in ATP) 
were similar. A concentration-dependent increase in the 
number of regulated genes was observed. From the data 
on the number of regulated genes (Fig. 1), it is clear that 
concentrations that do not result in a substantial reduction 
in viability do not cause regulation of a significant number 
of genes. At concentrations causing up to 30 % decrease 
in viability, a relatively limited number of genes were 
regulated, and at higher concentrations, where toxicity 
amounted to 30–50 %, a significant number of genes was 
regulated.
However, despite of a similar decrease in toxicity, the 
compounds have different effects on gene expression 
judged on the basis of a different number of regulated 
genes. In general, the large majority of genes regulated at 
the low concentrations were also regulated at the higher 
concentrations for each of the compounds (results not 
shown). Between the different compounds, similarities and 
differences were observed (see supplementary figure 2), 
which is not surprising as the tested compounds are known 
to cause cholestasis by different mechanisms. Further path-
way analysis of the regulated genes was performed to show 
overlap in regulated pathways and identify their potential 
relation with cholestasis (see below).
Canonical signaling pathway analysis
The Ingenuity Knowledge Base contains canonical path-
ways that are well-characterized metabolic and cell signal-
ing pathways. The differentially regulated genes as shown 
in Fig. 1 were scored against the canonical pathways, and 
the resulting scaled values for pathway enrichment are 
shown as a heatmap in Fig. 2. 
Figure 2 shows that many canonical pathways that are 
related to bile acid homeostasis and cholestasis are regu-
lated in the PCLS treated with the 5 cholestatic compounds 
in the presence of a portal vein concentration of a physi-
ological bile acid mix. Hepatic cholestasis appeared as one 
of the top 10 most significantly affected pathways. Moreo-
ver, signaling pathways such as FXR, LXR, PXR and VDR, 
which play a prominent role in cholestasis, are also signifi-
cantly affected. In addition, endoplasmic reticulum stress 
(ER stress), unfolded protein response and protein ubiquit-
ination pathways, known to play a role in bile acid-induced 
cholestasis process (Adachi et al. 2014), are significantly 
affected. Furthermore, the pathways involved in bile acid-
induced damage such as Nrf2-mediated stress response, 
coagulation system and complement activation appear 
affected. The observed patterns of activated genes appeared 
concentration dependent; nevertheless, there was a good 
overlap of the regulated genes at the different concentra-
tions. Therefore, for the comparison of the genes regulated 
in these different canonical pathways, the highest concen-
tration for each of the different cholestatic compounds was 
considered for further analysis. The genes that were regu-
lated significantly by at least one of the compounds in these 
Fig. 1  Number of genes dif-
ferentially regulated with a 
fold change of 1.5 and multiple 




different pathways are given in Tables 3, 4 and 5 and in the 
supplementary Tables 1–8, where downregulated genes are 
highlighted in blue and upregulated genes in orange.   
It is interesting to observe that the genes coding for 
transporters and metabolic enzymes in the hepatic cholesta-
sis pathway are downregulated (Table 3). It should be men-
tioned here that most of the genes involved in the hepatic 
cholestasis pathway are also part of the signaling pathways 
mentioned below.
The FXR pathway was the most significantly regulated 
pathway. The genes regulated in the human PCLS that are 
involved in FXR-mediated response are summarized in 
Table 4. It is apparent that many target genes involved in 
the FXR pathway such as BSEP, MRP2, MDR3, BACS, 
BAAT, FGF15 and PXR are downregulated. The LXR path-
way was also significantly downregulated in human PCLS 
exposed to cholestatic compounds and bile acids. The genes 
regulated in human PCLS that are involved in LXR-medi-
ated response are summarized in supplementary Table 1. 
Also, the genes involved in the cholesterol biosynthesis 
pathway were downregulated in human PCLS by the chole-
static compounds except for CP (supplementary Table 2). 
The downregulation of the cholesterol biosynthesis genes 
is well in line with the downregulation of the LXR target 
genes. As expected, also target genes in the PXR (supple-
mentary Table 3) and VDR (supplementary Table 4) path-
ways were regulated. Among the PXR target genes, some 
of the cytochrome P450 isoforms were upregulated ex vivo 
in the slices. In line with the published involvement of ER 
stress in cholestasis, the unfolded protein response pathway 
was significantly regulated and most of the genes involved 
in unfolded protein response (ER stress) were significantly 
upregulated (Table 5).
Complement and coagulation pathways were affected, 
and genes involved in those pathways were mostly down-
regulated as shown in supplementary Tables 5 and 6, 
respectively. NRF2-mediated oxidative stress response 
was affected, and upregulation of genes coding for heat 
shock proteins and the activation of transcription factors 
such as ATF4 and NRF2 were apparent (supplementary 
Table 7). In addition, the hepatic fibrosis pathway was 
affected, and some genes involved in the hepatic stellate 
cell activation were upregulated such as KLF6 (supple-
mentary Table 8).
Fig. 2  Heatmap of canonical 
pathway enrichment analysis 
results. Enrichment values [−
log (p value)] are scaled from 0 
to 3 (black to red). Compound 
exposures where no or very 
few genes were regulated were 
excluded (color figure online)
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Table 3  Genes involved in hepatic cholestasis pathway and their regulation after exposure to cholestatic drugs in human PCLS (color figure 
online)
Gene Symbol Gene description AN 75µM CP 30µM CS 15µM EE 75µM MT 100µM 
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4
ABCC3 ATP–binding cassette, sub–family C (CFTR/MRP), member 3
ABCG5 ATP-binding cassette, sub-family G (WHITE), member 5
ABCG8 ATP-binding cassette, sub-family G (WHITE), member 8
CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1
CYP8B1 cytochrome P450, family 8, subfamily B, polypeptide 1
GCGR glucagon receptor
IL1B interleukin 1, beta
IL1RL1 interleukin 1 receptor-like 1
IL1RN interleukin 1 receptor antagonist
IRAK2 interleukin-1 receptor-associated kinase 2
JUN jun proto-oncogene
NR0B2 nuclear receptor subfamily 0, group B, member 2
NR1H3 nuclear receptor subfamily 1, group H, member 3
NR1H4 nuclear receptor subfamily 1, group H, member 4
PPRC1
peroxisome proliferator-activated receptor gamma, coactivator-
related 1
RXRA retinoid X receptor, alpha
SLC22A7 solute carrier family 22 (organic anion transporter), member 7
TNFRSF1B tumor necrosis factor receptor superfamily, member 1B
–1.8 –1.5 –1.3 –1.6 –1.7
–2.1 –2.0 –1.1 –2.8 –3.6
–1.2 –1.1 –1.1 –1.3 –1.8
–1.5 –1.4 –1.1 –1.3 –1.5
–2.3 –1.7 –1.2 –1.7 –1.4
–1.3 –1.1 –1.7 –1.7 –1.5
–3.4 –2.3 –2.1 –1.7 1.1
–1.9 –1.7 –1.2 –1.4 1.0
–1.2 –1.1 –1.5 –1.1 –1.2
2.3 1.4 1.3 4.6 3.5
1.3 1.2 –1.2 1.1 1.9
1.6 1.5 1.4 1.3 1.1
1.3 1.5 2.0 1.7 1.6
–1.6 –1.2 –1.6 –1.4 –1.2
–1.8 –1.3 –1.3 –1.1 –1.0
–1.9 –1.3 –1.4 –1.2 –1.3
1.6 1.3 1.4 1.4 1.4
–1.5 –1.1 –1.3 –1.6 –1.7
–2.9 –2.6 –1.9 –2.1 –1.7
–1.5 1.0 –1.3 –1.2 1.1
Hepatic cholestasis
Significantly regulated genes with fold change ≤−1.5 or ≥1.5 are highlighted in orange and blue, respectively
Table 4  Genes involved in the FXR pathway and their regulation after exposure to cholestatic drugs in human PCLS (color figure online)
Gene Symbol Gene description AN 75µM CP 30µM CS 15µM EE 75µM MT 100µM 
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 4
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 11
ABCG5 ATP-binding cassette, sub-family G (WHITE), member 5




BAAT bile acid CoA:amino acid N-acyltransferase
C3 complement component 3
CYP8B1 cytochrome P450, family 8, subfamily B, polypeptide 1
FASN fatty acid synthase
FBP1 fructose-1,6-bisphosphatase 1
FETUB fetuin B
FGA fibrinogen alpha chain
ITIH4 inter-alpha-trypsin inhibitor heavy chain family, member 4
KNG1 kininogen 1
NR0B2 (SHP) nuclear receptor subfamily 0, group B, member 2
NR1H3 (LXR) nuclear receptor subfamily 1, group H, member 3
NR1H4 (FXR) nuclear receptor subfamily 1, group H, member 4
PON1 paraoxonase 1
RXRA retinoid X receptor, alpha
SCARB1 scavenger receptor class B, member 1
SDC1 syndecan 1
SERPINF2 serpin peptidase inhibitor, clade F , member 2
SLC22A7 solute carrier family 22 (organic anion transporter), member 7
SLC51B solute carrier family 51, beta subunit
SULT2A1 sulfotransferase family, cytosolic, 2A, member 1
–1.8 –1.5 –1.3 –1.6 –1.7
–2.1 –2.0 –1.1 –2.8 –3.6
–1.5 –1.4 –1.1 –1.3 –1.5
–2.3 –1.7 –1.2 –1.7 –1.4
–1.8 –1.4 –1.7 –1.3 1.0
–1.8 –1.8 –1.7 –1.4 –1.1
–1.9 –1.9 –1.9 –1.5 1.1
–1.7 –1.3 –1.4 –1.1 1.5
–1.7 –1.5 –1.5 –1.8 –2.0
CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1 –1.3 –1.1 –1.7 –1.7 –1.5
–3.5 –2.3 –2.1 –1.7 1.1
–2.1 1.5 –2.1 –1.2 1.2
–2.1 –1.9 –2.0 –1.4 1.2
–2.0 –1.8 –1.8 –1.6 –1.5
–2.1 –1.7 –1.6 –1.2 1.9
–1.5 –1.2 –1.6 –1.4 –1.4
–2.3 –1.8 –1.3 –1.9 –1.7
–1.6 –1.2 –1.6 –1.4 –1.2
–1.8 –1.3 –1.3 –1.1 –1.0
–1.9 –1.3 –1.4 –1.2 –1.3
–2.0 –1.9 –1.6 –1.4 1.4
–1.5 –1.1 –1.3 –1.6 –1.7
–2.2 –1.6 –1.4 –1.8 –1.6
–2.4 –1.4 –1.9 –1.8 –1.8
–1.8 –1.6 –1.6 –1.3 1.1
–2.9 –2.6 –1.9 –2.1 –1.7
–2.6 –1.9 –1.7 –2.4 –2.8
–2.1 –1.9 –1.8 –1.0 1.7
FXR signalling pathway




In this study, human PCLS were validated as an ex vivo 
model that reflects the drug-induced cholestasis processes 
using transcriptomic analysis. Hepatotoxicants that are 
known to induce cholestasis in human, such as cyclo-
sporine, chlorpromazine, ethinyl estradiol and methyl tes-
tosterone, clearly induced regulation of genes and path-
ways associated with cholestasis in human PCLS when 
incubated in the presence of bile acids. In addition, ANIT, a 
well-known cholestatic compound in rats, was included in 
the study, and showed a similar cholestatic gene expression 
pattern in human liver slices. From the data, it is clear that 
concentrations that do not cause a decrease in viability also 
do not lead to differential expression of a substantial num-
ber of genes. Also, the addition of 60 µM of bile acid mix 
to the incubation medium does not induce major changes in 
gene expression (data not shown). Pathway analysis clearly 
showed a gene expression pattern of cholestatic injury, 
which was concentration dependent for all drugs (Fig. 1 
and supplementary Figure 1). The direction of regulation 
of most genes was similar among the five tested cholestatic 
drugs, but there were differences with respect to the num-
ber of genes that were significantly regulated in each path-
way. Importantly, hepatic cholestasis was among the top 5 
regulated pathways. The majority of the pathways regulated 
in the human PCLS are represented in the adverse outcome 
pathway (AOP) for cholestasis as proposed by Vinken et al. 
(2013), including the primary direct cellular responses and 
secondary adaptive responses involved in bile acid-induced 
cholestatic injury, such as primary toxicity by NRF2-
mediated oxidative stress response, inflammation-mediated 
hepatic fibrosis, endoplasmic reticulum stress and activa-
tion of the coagulation and complement system. Moreover, 
signaling pathways such as FXR, LXR, PXR and VDR as 
well as the related cholesterol biosynthesis pathways were 
affected. The significantly regulated pathways are clearly 
distinct from the pathways regulated by paracetamol as 
published by us (Elferink et al. 2011). Moreover, the gene 
expression pattern obtained by these cholestatic com-
pounds was clearly distinct from those obtained after treat-
ment of PCLS of the same human livers with necrotic com-
pounds, which allowed us to develop a classification model 
and identify some classifier genes (Vatakuti et al. 2016). 
Together this indicates that the observed regulated path-
ways are at least to a large extent related to the cholestatic 
properties of the tested compounds. Further research with 
a higher number of human liver samples and more chole-
static drugs will be needed to identify key signature genes 
that best represent the key events during cholestasis and 
can identify compounds with cholestatic potential.
Since only the highest toxic concentration tested in our 
study induced significant gene expression changes related 
to cholestasis, we compared those concentrations with Cmax 
values in adult patients after a therapeutic dose in the sys-
temic blood, being 0.42 µM for chlorpromazine, 3.2 µM 
for cyclosporine, 8.2 nM for ethinylestradiol and 0.13 µM 
for methyl testosterone. The toxic concentration used in 
our PCLS study was quite well in the same range as the 
Cmax for chlorpromazine (~70× Cmax), and cyclosporine 
(~3× Cmax), but for ethinylestradiol (~9000× Cmax) and 
methyl testosterone (~770× Cmax), much higher concentra-
tions were used ex vivo. Cmax values could not be found 
for ANIT as it is studied so far only in animals. Although 
for some compounds we could only see evident changes 
at high concentrations, this is not unusual and the concen-
trations tested were similar to the concentrations tested in 
human hepatocytes as published in the TG-GATEs data-
base (http://toxico.nibiohn.go.jp/open-tggates/english/
search.html).
It is generally assumed that the accumulation of bile 
acids, cholesterol and bilirubin during onset and progres-
sion of cholestatic condition induces response processes 
characterized by the activation of nuclear receptors such 
as FXR, LXR, PXR and VDR, which triggers cellular 
adaption to counteract bile acid accumulation and thus 
Table 5  Genes involved in unfolded protein response (UPR) and their regulation after exposure to cholestatic drugs in human PCLS (color fig-
ure online)
Gene Symbol Gene description AN 75µM CP 30µM CS 15µM EE 75µM 100µM 
ATF4 acvang transcripon factor 4 2.3 1.5 1.8 1.3 1.2
DDIT3 (CHOP) DNA-damage-inducible transcript 3 2.9 1.2 1.8 1.8 2.9
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.7 1.0 3.0 1.4 1.0
ERN1 endoplasmic reculum to nucleus signaling 1 1.6 1.1 1.1 1.8 3.0
HSPA9 heat shock 70kDa protein 9 (mortalin) 1.9 1.1 1.7 1.4 1.3
HSPH1 heat shock 105kDa/110kDa protein 1 1.7 1.4 1.4 2.8 1.7
INSIG1 insulin induced gene 1 –2.5 1.3 –2.0 –1.7 –1.5
NFE2L2 nuclear factor, erythroid 2-like 2 1.5 1.1 1.2 1.0 1.1
SYVN1 synovial apoptosis inhibitor 1, synoviolin 1.5 1.0 1.8 1.1 –1.1
Unfolded protein response
Significantly regulated genes with fold change ≤−1.5 or ≥1.5 are highlighted in orange and blue, respectively
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cholestatic liver injury (Zollner and Trauner 2008; Wag-
ner et al. 2009). The farsenoid X receptor (FXR) acts as a 
sensor for intracellular bile acid levels (Makishima et al. 
1999), and activation of FXR (NR1H4) induces adap-
tive gene expression changes in response to accumulation 
of bile acids in cholestasis such as inhibition of bile acid 
synthesis, upregulation of phase I bile acid hydroxylation, 
phase II conjugation enzymes, and induction of the expres-
sion of canalicular and basolateral bile acid transporters. In 
contrast with this expected activation of FXR, in the human 
PCLS, the target genes in the FXR pathway were down-
regulated. Interestingly, a similar trend of downregulation 
of FXR target genes was observed in mouse PCLS after 
exposure to cholestatic drugs in the absence of bile acids 
(Szalowska et al. 2013). Important genes known to play 
a role in cholestasis such as ABCB4 (MDR3), ABCB11 
(BSEP) and NR0B2 (SHP) were downregulated in human 
PCLS exposed to bile acids and cholestatic drugs. Previ-
ously, we showed upregulation of SHP and downregulation 
of BSEP as a response to accumulation of bile acids after 
incubation of human PCLS with 100 μM CDCA (Jung 
et al. 2007). Either a limited increase in the concentration 
of the total bile acids particularly of CDCA in the hepato-
cytes or the presence of other bile acids such as LCA that 
can counteract the effect of CDCA (Yu et al. 2002) may 
be the cause for this difference. Lew et al. (2004) showed 
that FXR controls the gene expression of its target genes 
in a ligand-dependent fashion based on the individual bile 
acids. It is possible that FXR downregulation is due to 
combined effect of mixture of bile acids used in our experi-
ments instead of using only an FXR agonist such as CDCA 
reported in other PCLS studies where FXR target genes 
were upregulated (BSEP, SHP) (Jung et al. 2007). Con-
sistent with our data is the findings that antagonizing FXR 
activation is a mechanism for lithocholic acid-induced liver 
toxicity (Yu et al. 2002), whereas the synthetic FXR agonist 
GW4064 prevents intra- and extrahepatic cholestatic injury 
(Liu et al. 2003). However, BSEP downregulation may 
also indicate a direct effect of the tested cholestatic drugs 
on the regulation of the BSEP transporter, as potent BSEP 
inhibitors have been shown to downregulate BSEP expres-
sion in primary human hepatocytes (Garzel et al. 2014). 
In addition Kaimal et al. (2009) showed that the potent 
BSEP inhibitor troglitazone, which acts as FXR modula-
tor, antagonized the bile acid/FXR signaling pathway and 
significantly repressed bile acid-induced BSEP and SHP 
expression (Kaimal et al. 2009). Moreover, the decreased 
expression of FXR (Table 4) can at least partly explain 
this reduced FXR signaling. This is in line with the finding 
that both FXR and SHP expressions were reduced by 90 % 
or more in cholestatic patients (Demeilliers et al. 2006). 
Thus, based on our findings, it can be postulated that expo-
sure to cholestatic compounds could lead to compromised 
FXR-mediated adaptive responses, causing hepatic choles-
tasis. The liver X receptor (LXR) is involved in the regu-
lation of metabolism of lipids and cholesterol to bile acid 
catabolism. Activation of the LXR receptor is shown to pre-
vent toxicity from bile acid accumulation in female mice 
(Uppal et al. 2007). We found in human PCLS that the 
LXR pathway including the genes involved in cholesterol 
transport such as ABCG5 and ABCG8 was downregulated 
by the cholestatic drugs, which may indicate a loss of this 
protective action of LXR. In addition, the PXR and VDR 
pathways are downregulated due to the exposure of PCLS 
to the cholestatic drugs. The pregnane X receptor (PXR) is 
activated by drugs and endogenous molecules and plays a 
central role in their metabolism by induction of cytochrome 
P450 enzymes, conjugation enzymes and efflux transport-
ers. PXR activation also regulates bile acid synthesis, their 
metabolism and transport, cholesterol homeostasis and 
lipid metabolism. The exposure of the human PCLS to the 
cholestatic compounds resulted in upregulation of some of 
the phase I metabolic enzymes such as CYP1A2, CYP2C8 
and CYP2C9. However, again in contrast to the results 
obtained after incubation with 100 μM CDCA, there was 
no change in the expression of CYP7A1 involved in bile 
acid synthesis in human PCLS. The vitamin D recep-
tor (VDR) expression is restricted to non-parenchymal 
cells, such as biliary epithelial cells in the liver (Gascon-
Barré et al. 2003). VDR downregulation was not observed 
in our data, but RXR expression is down regulated. Since 
VDR acts as a heterodimer with RXR, it can be assumed 
that VDR function is compromised by this lack of RXR 
expression. Together, the reduced activation of FXR, LXR, 
PXR and VDR could be responsible for reduced adaptive 
responses to the effects of the cholestatic drugs and lead to 
development of cholestasis.
Oxidative stress is implicated to play a role in the patho-
genesis of drug-induced cholestasis as a result of bile acid 
accumulation (Tanaka et al. 2009; Copple et al. 2010; 
Anthérieu et al. 2013). Oxidative stress was also shown 
to play a major role as a primary causal event in the early 
CPZ-induced cholestasis in human HepaRG cells (Anthé-
rieu et al. 2013). In addition, the protective role of the 
NRF2-mediated oxidative stress response was reported 
in mice in response to ANIT-induced cholestasis (Tanaka 
et al. 2009). This NRF2-mediated oxidative stress response 
counteracts the cellular oxidative stress by induction of 
detoxifying and antioxidant enzymes, which also occurred 
ex vivo as ATF4 (activating transcription factor 4) was 
upregulated in the human PCLS treated with cholestatic 
drugs. ATF4 is known to increase the activation of phos-
phorylated NRF2 protein, key regulator of the oxidative 
stress response. This indicates that detoxifying mecha-
nisms are activated in the PCLS to alleviate the oxidative 
stress due to accumulating bile acids. Hepatic fibrosis and 
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hepatic stellate cell activation were also observed in human 
PCLS due to exposure to the cholestatic drugs. Accumu-
lation of bile acids by obstructive cholestasis (Tag et al. 
2015) was shown to lead to an inflammatory response 
in vivo which in turn leads to activation of hepatic stel-
late cells and liver fibrosis. We showed recently that rat 
and human PCLS can be a suitable model to identify the 
early fibrotic changes and fibrosis-inducing potential of a 
compound by transcriptomics (Vatakuti et al. 2015) or RT-
PCR (van de Bovenkamp et al. 2005; Westra et al. 2014) 
Early fibrotic response genes identified in rat PCLS such 
as KLF6 and SERPINE1 were upregulated in human PCLS 
indicating their prominent role in the early onset of fibro-
sis. A recent study revealed that endoplasmic reticulum 
stress is involved in the bile acid-induced hepatocellular 
injury (Adachi et al. 2014). In PCLS, ER stress, UPR and 
protein ubiquitination pathways were also among the most 
affected pathways. The UPR signaling pathway is activated 
in response to ER stress and promotes cell survival and 
adaptation. Our results suggest that ER stress, protein ubiq-
uitination and unfolded protein response UPR may be early 
cellular effects in drug-induced cholestasis.
Cholesterol is the starting material for the synthesis of 
bile acids in liver. Bile acid biosynthesis is the major cata-
bolic pathway for cholestasis. The genes involved in cho-
lesterol biosynthesis were downregulated in human PCLS 
indicating the adaptive response of hepatocytes to decrease 
cholesterol synthesis as a response to cholestatic drugs 
(supplementary table 2) as was also observed in mouse 
PCLS (Szalowska et al. 2013). Also, genes in the com-
plement system such as C3 and C5 were downregulated 
in human PCLS indicating possibly the adaptive response 
to the inflammation leading to fibrosis. The complement 
system is known to play a critical role in the pathogenesis 
of chronic liver disease (Qin and Gao 2006) and is regu-
lated by FXR in both human and rodents (Li et al. 2005). 
The coagulation system is one of the signaling pathways 
involved in cellular stress and injury. The coagulation sys-
tem is known to contribute to bile duct ligation-induced 
and ANIT-induced liver injury (Abdel-Salam et al. 2005; 
Luyendyk et al. 2009) in the rat. Downregulation of genes 
involved in the coagulation system was observed in human 
PCLS.
Comparison with human in vivo cholestasis
The results obtained in PCLS should preferably be vali-
dated by comparing with human liver tissue of patients 
suffering from drug-induced cholestasis. However, to the 
best of our knowledge, this data is not available. There-
fore, we compared our findings with gene expression data 
obtained from liver samples of patients with cholestasis 
due to biliary atresia and intrahepatic non-drug-induced 
cholestasis (Bessho et al. 2014). Despite the fact that these 
samples represent an end-stage disease situation and were 
mainly obtained from infants, comparison of the activated 
pathways between human PCLS and the patient samples 
revealed that there was good overlap with respect to the 
processes involved in cholestasis, although more pathways 
were affected in vivo than in the cholestatic PCLS (sup-
plementary Figure 3). The FXR pathway was affected both 
in vivo and ex vivo; however, in human PCLS, the genes 
involved in the FXR pathway were downregulated in con-
trast to the patient samples, where they were upregulated. 
The genes involved in the LXR pathway and cholesterol 
biosynthesis were mostly downregulated in both the human 
PCLS and the patient livers. Remarkably, among the PXR 
target genes, some of the cytochrome P450 isoforms were 
strongly downregulated in the human cholestatic livers 
in vivo but were not regulated or somewhat upregulated 
in human PCLS. Several genes involved in UPR response 
were upregulated after exposure to cholestatic drugs in 
human PCLS but were downregulated in in vivo cholesta-
sis (supplementary Figure 4). Genes involved in the com-
plement system were downregulated in both human PCLS 
and in patient samples. Liver fibrosis or hepatic stellate 
cell activation is observed both in human PCLS exposed 
to cholestatic drugs and in in vivo cholestasis. Structural 
alteration of tight junction proteins is observed in the bile 
duct-ligated cholestasis (Fallon et al. 1993). The tight junc-
tion signaling pathway is not activated in slices, but sig-
nificant activation is seen in patient samples (supplemen-
tary Figure 3). An explanation for the observed differences 
between in vivo data and the ex vivo data could be due to 
the different causes of cholestasis, the age of the patients 
or the large difference in time frame. In addition, we have 
performed an analysis of the data of Schröder et al. (2013) 
and focused on some important genes known to play a 
role in cholestasis. ABCB11 (BSEP), ABCB4 (MDR3), 
ABCG5 and NR0B2 (SHP) are downregulated in accord-
ance with the findings in our study. CYP8B1 is downregu-
lated similarly in both studies; CYP7A1 is not regulated in 
our dataset but surprisingly is upregulated in the dataset of 
Schroder et al. in contrast to the expected downregulation. 
In the cholestatic patients, an upregulation of the nuclear 
receptors NR1H4 (FXR) and NR1H3 (LXR) was observed 
in contrast to the observed downregulation in human PCLS, 
which could be due to the different causes of cholestasis or 
the large difference in time frame. Another reason could be 
the upregulation of RXRA in cholestatic patients in con-
trast to downregulation in human PCLS. Nuclear receptors 
such as FXR and LXR act in combination with RXRA as 
heterodimers. We observed the downregulation of RXRA 
in human PCLS across the tested cholestatic drugs and 
hence possibly explaining the downregulation of nuclear 




In conclusion, the transcriptomic analysis of human PCLS 
exposed to cholestatic drugs in the presence of bile acids 
revealed that this model reflects the primary toxicity pro-
cesses associated with hepatic cholestasis, and the related 
processes such as oxidative stress, ER stress and UPR 
response, and therefore seems to be promising for the 
future application in drug screening for cholestasis. The 
results suggest that decreased adaptive responses mediated 
via nuclear receptors are associated with these cholestatic 
effects. Our study demonstrates that human PCLS are a suit-
able model to identify biomarkers and possible mechanisms 
of toxicity of cholestatic compounds, when incubated in 
the presence of a physiological concentration of bile acids. 
However, at this moment, this model cannot be used for 
screening of large amounts of drug candidates due to the 
limitation of the availability of fresh human tissue. As soon 
as successful cryopreservation methods will be established, 
the availability of the tissue will become much better, and 
will become similar to that for human hepatocytes. Moreo-
ver, for full mechanistic inside on drug-induced cholesta-
sis, additional time points of exposure of the PCLS, more 
human liver samples and more cholestatic drugs should be 
tested to better understand the transcriptomic responses with 
respect to accompanying cholestatic events.
Mechanistic insights such as downregulation of choles-
terol biosynthesis, ER stress response and NRF2-mediated 
oxidative stress response could be included in the adverse 
outcome pathway of cholestasis.
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